drugset / Trial / NCT04672135
A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127
RandomizedSequentialDouble-blindTreatment
Summary
This is a phase 1 randomized double blind, first in human (FIH) study with the novel oral Alzheimer drug candidate REM0046127, which consists of two main parts, a single ascending dose (SAD) study with 7 cohorts followed by a multiple ascending dose (MAD) study with 2 cohorts.
Timeline
- Start
- 2020-11-09
- Primary completion
- 2022-04-01
- Completion
- 2022-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | REM0046127 | Small molecule | 35 mg | Oral |
| Comparator | REM0046127 | Small molecule | 2000 mg | Oral |